胃食道逆流症治療市場（按治療類型、通路、給藥途徑、劑型和患者最終用戶分類）－全球預測 2025-2032

預計到 2032 年，胃食道逆流症藥物市場將成長至 91.8 億美元，複合年成長率為 5.16%。

簡潔而全面地介紹不斷發展的治療前景、臨床促進因素、患者需求以及影響 GERD 治療的策略重點

由於持續的症狀負擔、不斷發展的臨床路徑以及不斷變化的患者期​​望，胃食道逆流症 (GERD) 已成為消化器官系統保健領域的核心。現代臨床實踐在長期確立的抑酸療法與更注重長期安全性、按需治療以及輔助性機械和內視鏡干預措施之間取得了平衡。因此，臨床、商業和監管相關人員正在重新評估治療重點和投資決策。

因此，臨床醫師越來越注重區分患者的表現型、最佳化診斷流程，並根據症狀模式和療效制定個人化治療方案。治療方案的重大轉變、新型抑酸藥物的興起以及微創手術的普及，正在拓寬治療頻譜，但同時又不影響實證藥物治療的核心作用。同時，支付方監管、學名藥競爭和門診病人管理等方面的趨勢正在重塑處方和分銷行為。

這些綜合動態為產品開發商、製造商和醫療保健系統帶來了複雜性和機會。因此，清晰的策略需要綜合考慮臨床趨勢、供應鏈現狀和以​​患者為中心的交付模式，從而做出切實可行的決策，在改善療效的同時保持商業性可行性。

透過藥物創新、程序介入、以患者為中心的數位解決方案和診斷，重新定義 GERD 治療途徑的轉型轉變

隨著技術創新的融合、醫療服務模式的不斷變化以及人們對安全性和個人化治療期望的不斷提高，胃食道逆流症 (GERD) 的治療格局正在改變。在藥理學方面，新型抑酸劑和替代機制的出現迫使臨床醫生重新思考長期治療策略，而越來越多的證據和特定市場的監管核准正在推出超越傳統質子幫浦阻斷劑的具有臨床意義的治療方案。同時，微創和器械介導治療方法正從小眾轉診中心走向更廣泛的臨床應用，為尋求緩解難治性疾病和藥物依賴的患者提供新的治療選擇。

同時，診斷技術也日益精細化，門診和電阻監測的增強促進了表現型主導的治療。支持依從性、症狀追蹤和遠端醫療諮詢的數位化工具正在重塑持續護理，並實現更快速的治療滴定。此外，學名藥與品牌藥創新之間的相互作用正在推動策略性產品組合調整、夥伴關係模式和上市策略。因此，製造商和醫療保健提供者必須應對一個多維度的環境，在這個環境中，臨床差異化、成本效益和患者體驗決定了藥物的吸收和持續使用。

對 2025 年關稅轉變將如何重塑 GERD 的供應鏈、籌資策略以及整個價值鏈的商業性決策進行基於證據的評估

貿易政策發展，包括2025年生效的關稅調整，將產生累積壓力，波及藥品生產、分銷和採購領域。原料、活性藥物成分、設備零件和包裝的關稅可能會提高投入成本，對利潤微薄的學名藥和品牌藥製造商構成挑戰。為此，許多公司正在加速供應商多元化，增加對區域製造地的依賴，並尋求更長期的合約保護，以穩定關鍵投入品的取得。

因此，採購團隊和商業領袖正在重新評估其採購佈局，以降低進口關稅和運輸波動帶來的風險。對於專業醫療設備和契約製造而言，關稅驅動的成本上漲促使他們在法規和工作條件允許的情況下更傾向於近岸或在岸生產，儘管資本和技術限制可能會限制短期轉移。從分銷角度來看，由於成本上漲與付款方對可負擔性和基於價值的合約的預期相交織，醫院處方集和門診護理提供者可能面臨與供應商談判的更大壓力。

綜上所述，這些動態凸顯了主動的供應鏈風險評估、情境規劃和策略供應商夥伴關係關係對於減輕關稅影響的重要性。在日益複雜的貿易環境中，投資供應鏈透明度、自適應採購和庫存最佳化的公司將能夠保持臨床連續性，同時保護商業性利潤。

將治療方式、分銷管道、給藥途徑和形式以及患者最終用戶情況與策略重點聯繫起來的細分主導洞察

該細分提供了一個框架，用於將治療方法開發、商業策略和分銷策略與患者需求和臨床環境相結合。根據治療類型，市場分為制酸劑、H2受體拮抗劑、促動力劑和質子幫浦阻斷劑。 H2受體拮抗劑進一步分為品牌藥和學名藥。質子幫浦阻斷劑進一步分為品牌藥和學名藥。這種治療水準的細分突顯了速效非處方藥、按需處方藥和長效抑制療法的共存，突顯了創新和配方改良可以創造臨床優勢的領域。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

• 增加鉀競爭性酸阻斷劑在難治性胃食道逆流症患者的臨床應用
• 整合人工智慧驅動的數位健康平台，用於遠端監控和 GERD 治療的依從性
• 微創內視鏡抗逆流方法（如 TIF 和 MSA）在臨床上的廣泛應用
• 新興微生物組標靶治療策略作為GERD管理的輔助方法
• 利用遺傳生物標記的個人化治療流程最佳化 GERD 治療結果

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 胃食道逆流症治療藥物市場（依治療類型）

• 制酸劑
• H2受體拮抗劑
  • 品牌
  • 非專利的
• 促動力
• 質子幫浦抑制劑
  • 品牌
  • 非專利的

9. 胃食道逆流症藥物市場（依分銷管道）

• 醫院藥房
• 網路藥局
• 零售藥局

10. 胃食道逆流症藥物市場（依給藥途徑）

• 靜脈
• 口服

第11章胃食道逆流症治療市場（按劑型）

• 膠囊
• 液體
• 暫停
• 藥片

12. GERD藥物市場患者最終用戶

• 居家照護環境
• 醫院
• 專科診所

13. GERD治療市場（按地區）

• 美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第 14 章胃食道逆流症藥物市場（依類別）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

15. GERD治療市場（按國家）

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第16章競爭格局

• 2024年市佔率分析
• 2024年FPNV定位矩陣
• 競爭分析
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson Services, Inc.
  • Pfizer Inc.
  • Sanofi SA
  • GlaxoSmithKline plc
  • Bayer AG
  • Merck Sharp & Dohme Corp.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.

The Gastroesophageal Reflux Disease Therapeutics Market is projected to grow by USD 9.18 billion at a CAGR of 5.16% by 2032.

A concise yet comprehensive introduction to the evolving therapeutic landscape, clinical drivers, patient needs, and strategic priorities shaping GERD treatments

Gastroesophageal reflux disease occupies a central position in digestive healthcare, driven by persistent symptom burden, evolving clinical pathways, and shifting patient expectations. In recent years clinical practice has balanced long-established acid suppression approaches with growing attention to long-term safety, on-demand management, and complementary mechanical or endoscopic interventions. As a result, stakeholders across clinical, commercial, and regulatory spheres are reassessing therapeutic priorities and investment decisions.

Consequently, clinicians are increasingly focused on differentiating patient phenotypes, optimizing diagnostic algorithms, and tailoring treatments to symptom patterns and treatment response. Pivotal changes in therapeutic options, the rise of novel acid suppression classes, and broader access to minimally invasive procedures have widened the spectrum of care without eliminating the central role of evidence-based pharmacotherapy. At the same time, payer scrutiny, generics competition, and outpatient management trends are reshaping prescribing and distribution behaviors.

Taken together, these dynamics create both complexity and opportunity for product developers, manufacturers, and health systems. Therefore, strategic clarity requires an integrated view that connects clinical trends, supply chain realities, and patient-centered delivery models to inform pragmatic decisions that enhance outcomes while maintaining commercial viability.

Transformative shifts redefining GERD care pathways through pharmacologic innovation, procedural interventions, and patient-centric digital solutions and diagnostics

The GERD therapeutic landscape is undergoing transformative shifts as innovation converges with changing care delivery models and heightened expectations for safety and personalization. On the pharmacologic front, new classes of acid suppression and alternative mechanisms are prompting clinicians to reconsider long-term management strategies, while growing evidence and regulatory approvals in select markets have introduced clinically meaningful options beyond traditional proton pump inhibitors. In parallel, minimally invasive and device-mediated procedures have moved from niche referral centers toward broader clinical adoption, offering alternatives for refractory disease and patients seeking reduced pharmacologic dependence.

Meanwhile, diagnostics are becoming more nuanced, with enhanced ambulatory and impedance monitoring facilitating phenotype-driven therapy. Digital tools that support adherence, symptom tracking, and telehealth consultations are reshaping continuity of care and enabling more responsive titration of therapies. Moreover, the interplay between generics and branded innovation is driving strategic portfolio adjustments, partnership models, and go-to-market approaches. As a result, manufacturers and providers must navigate a multidimensional environment where clinical differentiation, cost-effectiveness, and patient experience determine uptake and sustained use.

An evidence-based appraisal of how 2025 tariff shifts cumulatively reshape GERD supply chains, procurement strategies, and commercial decision-making across the value chain

Trade policy developments, including tariff adjustments implemented during 2025, introduce cumulative pressures that reverberate across pharmaceutical manufacturing, distribution, and procurement. Tariffs on raw materials, active pharmaceutical ingredients, device components, and packaging can elevate input costs, thereby challenging manufacturers that operate on narrow margins in generic and branded segments alike. In response, many organizations accelerate supplier diversification, increase reliance on regional manufacturing hubs, and pursue longer-term contractual protections to stabilize access to critical inputs.

Consequently, procurement teams and commercial leaders are reassessing sourcing footprints to reduce exposure to import duties and transportation volatility. For specialty devices and contract manufacturing, tariff-induced cost increases tend to favor near-shore or onshore production where regulatory and labor conditions permit, though capital and technical constraints can limit near-term shifts. From a distribution perspective, hospital formularies and outpatient providers may face heightened negotiation pressure with suppliers as cost escalation intersects with payer expectations for affordability and value-based contracting.

Taken together, these dynamics highlight the importance of proactive supply chain risk assessment, scenario planning, and strategic supplier partnerships to mitigate tariff impacts. Firms that invest in supply chain transparency, adaptive sourcing, and inventory optimization can preserve clinical continuity while protecting commercial margins in an increasingly complex trade environment.

Segment-driven insights that connect treatment modalities, distribution channels, routes and forms of administration, and patient end-user contexts to strategic priorities

Segmentation provides the framework to align therapeutic development, commercial tactics, and distribution strategies with patient needs and clinical settings. Based on Treatment Type, market is studied across Antacids, H2 Receptor Antagonists, Prokinetics, and Proton Pump Inhibitors. The H2 Receptor Antagonists is further studied across Branded and Generic. The Proton Pump Inhibitors is further studied across Branded and Generic. This treatment-level granularity underscores the coexistence of rapid-onset OTC options, on-demand prescriptions, and durable suppression therapies, and it clarifies where innovation or reformulation can create clinical advantage.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. This distribution perspective reveals differential access patterns for acute inpatient care versus chronic outpatient management, and it highlights the growing importance of e-commerce for therapy continuity and adherence. Based on Route Of Administration, market is studied across Intravenous and Oral. Intravenous formulations remain critical for perioperative and hospitalized patients, while oral therapies dominate ambulatory care and home treatment strategies. Based on Dosage Form, market is studied across Capsule, Liquid, Suspension, and Tablet. Dosage form diversity supports age- and comorbidity-appropriate prescribing and adherence initiatives, particularly for pediatric, geriatric, and dysphagia-prone populations. Based on Patient End User, market is studied across Home Care Settings, Hospitals, and Specialty Clinics. Understanding end-user dynamics guides commercial outreach, patient support programs, and clinical education to ensure therapy alignment with care settings and patient expectations.

Therefore, segmentation-led insight enables targeted R&D prioritization, precise channel strategies, and tailored clinical support that collectively improve uptake and patient outcomes.

Regional clinical, regulatory, and supply chain nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that define differentiated strategic imperatives

Regional dynamics materially influence clinical practice patterns, regulatory timelines, and supply chain architectures, creating differentiated strategic imperatives across the globe. In the Americas, clinical practice is characterized by widespread adoption of established acid-suppression therapies, growing outpatient management, and a competitive landscape that incentivizes both branded differentiation and generic efficiency. Health systems and payers often emphasize real-world outcomes and formulary alignment, which in turn shapes provider prescribing and manufacturer access strategies.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable healthcare infrastructures demand regionally adapted approaches. Some countries prioritize value assessments and cost-effectiveness, while others emphasize access and primary care management. Consequently, manufacturers must align dossier development, pricing strategies, and local market partnerships to navigate reimbursement pathways and cultivate specialist referral networks. In Asia-Pacific, rapid urbanization, changing dietary patterns, and shifting diagnostic awareness have influenced prevalence and treatment demand. Additionally, certain markets in the region have been early adopters of new acid-suppression technologies, and manufacturing capacity in Asia-Pacific remains a strategic asset for both regional supply and global export.

Across these regions, regulatory trends, clinical guideline updates, and tariff considerations interact to influence launch sequencing, procurement planning, and local commercial models. Recognizing these regional nuances enables more precise investment prioritization and executional planning.

Strategic behaviors and competitive positioning among pharmaceutical, device, and manufacturing stakeholders that determine commercial and clinical success in GERD therapeutics

Companies operating in the GERD therapeutics space are pursuing a spectrum of strategic moves to preserve competitiveness and capture clinical relevance. Established pharmaceutical firms are balancing lifecycle management for long-standing acid-suppression products with selective investments in novel mechanisms and reformulations that address safety, adherence, and on-demand use. Generic manufacturers continue to optimize cost structures and expand distribution partnerships to maintain penetration across retail and hospital channels, while specialized device companies focus on clinical evidence generation to broaden adoption of endoscopic and implantable solutions.

Additionally, contract development and manufacturing organizations play an increasingly pivotal role as companies seek flexible, regulatory-compliant production capacity that supports both oral and intravenous forms across multiple dosage formats. Strategic collaborations between pharmaceutical developers and digital health vendors are emerging to create patient support ecosystems that improve adherence and capture real-world data. In parallel, commercial teams are refining payer engagement strategies to emphasize value-based outcomes and to secure formulary positioning amid heightened cost scrutiny. Collectively, these organizational approaches reflect an ecosystem where clinical differentiation, evidence generation, and operational resilience determine long-term success.

Actionable recommendations for leaders to strengthen supply chains, clinical differentiation, payer engagement, digital support, and regulatory alignment in GERD care

Industry leaders should adopt a multi-pronged strategy that aligns clinical innovation with operational resilience and market-facing agility. First, prioritize diversified and resilient supply chains by qualifying alternate suppliers for key APIs and components, investing in regional manufacturing partnerships, and implementing advanced inventory and demand-sensing capabilities to mitigate tariff and logistics volatility. Second, advance therapeutic differentiation by investing in clinical programs that clarify patient phenotypes, demonstrate comparative safety for long-term use, and evaluate combination or adjunctive approaches that reduce dependence on chronic high-dose acid suppression.

Third, strengthen payer and provider engagement through real-world evidence programs, outcomes-based contracting pilots, and targeted educational initiatives aimed at specialty clinics and hospital formularies to communicate value propositions effectively. Fourth, accelerate digital and patient support offerings that enhance adherence, personalized dosing, and telehealth integration, thereby improving outcomes and reducing unnecessary escalation to invasive procedures. Fifth, tailor commercial models across distribution channels by optimizing online pharmacy partnerships for chronic therapy continuity while maintaining hospital and retail access for acute and inpatient settings. Finally, ensure regulatory alignment by proactively engaging authorities on labeling, safety monitoring, and post-market evidence generation to facilitate access and maintain clinician confidence.

By executing these recommendations concurrently, organizations can protect margins, enhance patient outcomes, and sustain competitive advantage in a rapidly evolving therapeutic landscape.

A robust mixed-methods research methodology combining expert interviews, literature synthesis, supply chain mapping, and scenario analysis to validate insights and recommendations

The analysis underpinning this executive summary integrates a mixed-methods research approach to ensure depth, validity, and practical relevance. Primary qualitative inputs include structured interviews with clinical key opinion leaders, hospital pharmacists, specialty clinic directors, and senior procurement professionals to capture frontline perspectives on prescribing behavior, device adoption, and supply chain risks. Secondary research synthesized peer-reviewed literature, clinical guideline updates, public regulatory filings, and product monographs to validate therapeutic mechanisms, recent approvals, and diagnostic advancements.

Operational and commercial dimensions were examined through supply chain mapping exercises, review of import/export exposure, and scenario-based tariff impact modeling to identify stress points and mitigation options. Data triangulation methods were applied to reconcile divergent inputs and to ensure consistent interpretation across clinical, regulatory, and commercial domains. Finally, stakeholder validation workshops were conducted to refine conclusions, stress-test recommendations, and align insights with pragmatic implementation pathways for manufacturers, providers, and distributors.

This methodological blend of qualitative and quantitative techniques delivers a holistic perspective designed to support strategic decision-making without relying solely on single-source data points.

A concise conclusion highlighting emerging opportunities, operational challenges, and the integrated priorities that will shape future GERD therapeutic strategies

In summary, the GERD therapeutics ecosystem is characterized by steady clinical demand, meaningful innovation, and mounting operational complexity. Novel pharmacologic classes and minimally invasive procedures expand treatment choices, while evolving diagnostics and digital tools enable more precise, patient-centered care. At the same time, commercial and supply chain pressures, including tariff dynamics and distribution shifts, require companies to rethink sourcing, manufacturing footprints, and channel engagement.

Looking ahead, sustained success will depend on the ability to integrate clinical differentiation with resilient operations and evidence-led payer discussions. Organizations that invest in targeted clinical programs, diversify supply chains, and deploy digital adherence solutions will be better positioned to respond to regional nuances and evolving clinical guidelines. As stakeholders navigate this landscape, continuous alignment between R&D priorities, commercial execution, and patient support will be essential to deliver improved outcomes and long-term value.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Growing clinical adoption of potassium-competitive acid blockers for refractory GERD patients
• 5.2. Integration of AI-driven digital health platforms for remote monitoring and adherence in GERD therapy
• 5.3. Expansion of minimally invasive endoscopic reflux barrier techniques such as TIF and MSA in clinical practice
• 5.4. Emergence of microbiome-targeted therapeutic strategies as adjunctive approaches for GERD management
• 5.5. Personalized treatment algorithms leveraging genetic biomarkers to optimize GERD therapeutic outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastroesophageal Reflux Disease Therapeutics Market, by Treatment Type

• 8.1. Antacids
• 8.2. H2 Receptor Antagonists
  • 8.2.1. Branded
  • 8.2.2. Generic
• 8.3. Prokinetics
• 8.4. Proton Pump Inhibitors
  • 8.4.1. Branded
  • 8.4.2. Generic

9. Gastroesophageal Reflux Disease Therapeutics Market, by Distribution Channel

• 9.1. Hospital Pharmacies
• 9.2. Online Pharmacies
• 9.3. Retail Pharmacies

10. Gastroesophageal Reflux Disease Therapeutics Market, by Route Of Administration

• 10.1. Intravenous
• 10.2. Oral

11. Gastroesophageal Reflux Disease Therapeutics Market, by Dosage Form

• 11.1. Capsule
• 11.2. Liquid
• 11.3. Suspension
• 11.4. Tablet

12. Gastroesophageal Reflux Disease Therapeutics Market, by Patient End User

• 12.1. Home Care Settings
• 12.2. Hospitals
• 12.3. Specialty Clinics

13. Gastroesophageal Reflux Disease Therapeutics Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Gastroesophageal Reflux Disease Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Gastroesophageal Reflux Disease Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. AstraZeneca PLC
  • 16.3.2. Takeda Pharmaceutical Company Limited
  • 16.3.3. Johnson & Johnson Services, Inc.
  • 16.3.4. Pfizer Inc.
  • 16.3.5. Sanofi S.A.
  • 16.3.6. GlaxoSmithKline plc
  • 16.3.7. Bayer AG
  • 16.3.8. Merck Sharp & Dohme Corp.
  • 16.3.9. Novartis AG
  • 16.3.10. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROKINETICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 142. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 143. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 144. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 145. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 146. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 147. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 148. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
• TABLE 157. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 160. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 161. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 162. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 163. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 164. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 165. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 166. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
• TABLE 173. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 176. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 177. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 178. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 179. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 180. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 181. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 182. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 183. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 184. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
• TABLE 189. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 190. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 191. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 192. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 193. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 194. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
• TABLE 221. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 224. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 225. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 226. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 227. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 228. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 229. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 230. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 231. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 232. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 233. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 234. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 235. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
• TABLE 236. MIDDLE EAST GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
• TABLE 237. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 240. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 241. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 242. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 243. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 244. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2025-2032 (USD MILLION)
• TABLE 245. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 246. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 247. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 248. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 249. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 250. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 251. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2018-2024 (USD MILLION)
• TABLE 252. AFRICA GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PATIENT END USER, 2025-2032 (USD MILLION)
• TABLE 253. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
• TABLE 256. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
• TABLE 257. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
• TABLE 258. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY H2 RECEPTOR ANTAGONISTS, 2025-2032 (USD MILLION)
• TABLE 259. ASIA-PACIFIC GASTROESOPHAGEAL REFLUX DISEASE THERAPEUTICS MARKET SIZE, BY PROTON PUMP INHIBITORS, 2018-2024 (USD MILLION)
• TABLE 260. ASI